Vasoactive Intestinal Peptide

VIP is an endogenous 28-amino-acid neuropeptide of the secretin/glucagon superfamily that signals through two class B G-protein-coupled receptors — VPAC1 and VPAC2 — both widely distributed across immune, vascular, neural, and endocrine tissue. Receptor engagement couples primarily to Gαs → adenylyl cyclase → cAMP → PKA, with secondary Gq/PLC/Ca²⁺ signaling depending on cell type. That single upstream switch explains why one peptide reaches into immune tone, vascular diameter, circadian phase, and hair follicle immune privilege at the same time.

cAMP-Driven Immune Rebalancing#

The most clinically relevant arm of VIP signaling is its ability to downshift NF-κB-driven cytokine output. Elevated cAMP in myeloid and T-cell lineages suppresses TNF-α, IL-6, and IL-12 production while biasing dendritic cells toward a tolerogenic phenotype. The net effect is expansion of CD4⁺CD25⁺ regulatory T cells and a reduction in the Th1/Th17 bias that drives chronic inflammatory states like CIRS, long-COVID, and autoimmune flares.

"VIP potently inhibits proinflammatory cytokine production, including TNF-α and IL-6, and promotes the expansion of regulatory T cells and tolerogenic dendritic cells." — Delgado M, Pozo D, Ganea D. Journal of Leukocyte Biology, 2003

This is the pathway that users targeting post-mold recovery, post-viral neuroinflammation, and systemic immune dysregulation are actually recruiting when an intranasal protocol is run.

Selective Pulmonary and Systemic Vasodilation#

VPAC1 is densely expressed on pulmonary vascular smooth muscle. cAMP elevation there inhibits myosin light chain kinase and drops vascular tone — preferentially in the pulmonary bed, which is why inhaled aviptadil produces selective pulmonary vasodilation without tanking systemic pressure.

"Inhalation of a single dose of 100 µg VIP led to significant selective pulmonary vasodilation, with no evidence of systemic hypotension in patients with pulmonary arterial hypertension." — Leuchte HH, Baezner C, Baumgartner RA, et al. European Respiratory Journal, 2008

The practical read-through: this is the mechanism behind the niche use of inhaled VIP to offload right-ventricular afterload in users carrying elevated PA pressures from heavy AAS stacks — conceptually adjacent to daily low-dose tadalafil, not a replacement for it.

Circadian and Neuroendocrine Signaling#

VIP is the dominant coupling peptide within the suprachiasmatic nucleus. VPAC2 activation on SCN neurons synchronizes firing across the master clock and sets the phase of downstream peripheral oscillators — cortisol rhythm, melatonin onset, core body temperature. It also modulates pituitary prolactin, GH pulsatility, and glucose-dependent insulin release.

The actionable consequence: VIP is a phase cue, not a sedative. AM-weighted dosing reinforces an earlier chronotype and cleaner sleep onset; evening administration fragments sleep and is the single most common self-reported reason for "VIP didn't work for me."

Perifollicular Immune Privilege and Hair#

Hair follicles maintain immune privilege in part through perifollicular VIP-positive nerve fibers that dampen local antigen presentation. When that VIP tone is lost, the follicle becomes visible to CD8⁺ T cells — the collapse that drives alopecia areata.

"VIP-deficient mice and human lesional skin both revealed reduced perifollicular VIP and increased collapse of hair follicle immune privilege, suggesting a protective role for VIP against alopecia areata progression." — Bertolini M, Pretzlaff M, Sulk M, et al. British Journal of Dermatology, 2016

This positions VIP as a legitimate adjunct for autoimmune-pattern (AA-type) shedding — patchy loss, acute diffuse telogen effluvium triggered by viral or inflammatory insult — but not as a substitute for 5-AR inhibition in androgenic loss. Finasteride/dutasteride and topical AR antagonists remain the primary tools for MPB; VIP addresses a different mechanism entirely.

Neuropeptide Crosstalk and Cognition#

Within the hippocampus, VPAC1 and VPAC2 exert opposing effects on GABAergic transmission, fine-tuning excitatory/inhibitory balance. Combined with VIP's role in cerebral vasodilation and suppression of neuroinflammatory cytokines crossing a compromised blood-brain barrier, this is the mechanistic basis for the "brain fog lifts" reports common in long-COVID and post-mold protocols — the cognitive benefit is a downstream consequence of reduced central neuroinflammation plus improved cerebral perfusion, not a direct nootropic effect.

Common (most users)#

• Facial flushing and transient warmth — the most frequently reported effect, driven by VIP's vasodilatory action. Self-limiting within 15–30 minutes. Dose timing away from social or training windows resolves the complaint; no intervention needed.
• Mild headache in the first 1–2 weeks — typically resolves as the subject pool adapts. Hydration and magnesium glycinate 300–400mg in the evening blunt incidence. If persistent, the protocol is titrated down to 25 mcg 1×/day for a week before re-escalating.
• Loose stool or increased GI motility — reflects VIP's native role as a gut secretagogue. Usually transient over the first 3–7 days. Splitting the dose further (e.g. 25 mcg AM + 25 mcg midday) rather than front-loading 50 mcg in one spray resolves most cases.
• Nasal irritation or mucosal dryness — more often a vehicle issue than a peptide issue. Rotating nostrils per spray, ensuring the reconstitution saline is fresh, and a saline rinse between doses mitigate the complaint.
• Mild lightheadedness on standing — consistent with systemic vasodilation. Dose while seated and remain seated for 2–3 minutes post-administration. Salt and fluid intake should be adequate, particularly on low-carb protocols.

"No significant adverse events were encountered in this cohort of 20 subjects treated with VIP, and multi-symptom improvement alongside normalization of inflammatory markers was documented over an 18 month open-label observational trial." — Shoemaker, House & Ryan, Health (2013)

Uncommon (dose-dependent or individual)#

• Sleep fragmentation / vivid dreams — VIP is the dominant signaling peptide of the SCN, and evening dosing phase-shifts the master clock. The fix is structural: all dosing stays AM-weighted, with the last spray no later than early afternoon.
• Palpitations or mild tachycardia — more common with inhaled aerosolized aviptadil than with 50 mcg intranasal. If noted, the inhaled route is dropped and the protocol reverts to intranasal only. Check resting HR and BP trends; back off if resting HR climbs >10 bpm above baseline.
• Transient hypotension — dose-dependent, more likely at the upper Shoemaker ceiling (200 mcg/day) or when stacked with daily tadalafil, telmisartan, or other antihypertensives. A home BP cuff is cheap insurance; if systolic drops below 100 mmHg, the dose is halved.
• Jaw tension or flushing asymmetry — occasionally reported with higher-dose intranasal protocols. Usually a sign the spray is being delivered unevenly; reconstitution volume and pump priming should be verified.
• Blunted response after 4–6 weeks — not an adverse effect per se, but worth noting: degraded product is the usual culprit. Reconstituted VIP loses potency quickly with freeze-thaw cycles or room-temp storage. A fresh vial often restores the signal before any dose escalation is warranted.
• Bloodwork to check at 8–12 weeks on longer protocols: CMP, basic lipid panel, and — for users running it for CIRS/post-viral indications — TGF-β1, C4a, MSH, VEGF, MMP9.

Rare but serious#

• Significant hypotensive episode — primarily an IV or high-dose inhaled concern; essentially unreported at 50 mcg intranasal. Warning signs: syncope, visual greying on standing, systolic <90 mmHg. The protocol is stopped and volume status assessed.
• Severe bronchospasm or paradoxical pulmonary reaction — documented rarely with inhaled aviptadil in pulmonary hypertension research. Not relevant to the intranasal route but worth flagging for anyone experimenting with nebulized formulations.
• Unmasking of an occult neuroendocrine tumor — theoretical. VIP receptors are upregulated on many tumor types (pancreatic NET, breast, prostate, VIPoma). New-onset persistent watery diarrhea, unexplained flushing that does not resolve with dose reduction, or abnormal weight loss warrants workup and cessation.
• Allergic / hypersensitivity reaction to reconstituted product — rare and more often a reaction to bacteriostatic saline preservatives than to the 28-aa peptide itself. Facial swelling, urticaria, or wheeze is a hard stop.

"Inhalation of a single dose of 100 µg VIP led to significant selective pulmonary vasodilation, with no evidence of systemic hypotension in patients with pulmonary arterial hypertension." — Leuchte et al., European Respiratory Journal (2008)

Hard contraindications#

• Active malignancy, particularly neuroendocrine tumors. VPAC1/VPAC2 receptors are overexpressed on pancreatic NETs, VIPoma, breast, and prostate cancers. Chronic VIP administration in this context is contraindicated.
• Known VIPoma or pheochromocytoma. Adding exogenous VIP to a tumor already secreting vasoactive peptides is a line that does not get crossed.
• Acute porphyria. Standard neuropeptide caution.
• Severe baseline hypotension, or concurrent high-dose nitrate therapy. Stacking vasodilators is the mechanism of concern. Daily low-dose tadalafil (2.5–5 mg) is tolerated by most but warrants BP monitoring; nitrates are a hard no.
• Pregnancy and lactation. No data. Not used.
• Untreated ongoing mold / water-damaged-building exposure (for CIRS-indicated protocols). Not a safety contraindication in the toxicological sense, but VIP will suppress symptoms without resolving the driver and users relapse harder on cessation. The Shoemaker protocol is explicit: exposure elimination comes first.

"VIP potently inhibits proinflammatory cytokine production, including TNF-α and IL-6, and promotes the expansion of regulatory T cells and tolerogenic dendritic cells." — Delgado, Pozo & Ganea, J. Leukocyte Biology (2003)

Gender-specific and PCT considerations#

VIP is non-hormonal and does not suppress the HPTA. Dosing is uniform across the subject pool — there is no sex-based ladder, no virilization concern, and no PCT is required on cessation. The Shoemaker cohort data actually document restoration of testosterone and estradiol toward reference ranges in deficient subjects, consistent with VIP's role in pituitary regulation rather than suppression. For users running VIP alongside an AAS cycle, it does not replace or interfere with a standard SERM-based PCT and can be continued through the recovery phase without modification.

Pregnancy and lactation remain a hard exclusion on absence-of-data grounds. For the alopecia areata use case documented by Bertolini et al. (2016), the risk/benefit profile for women of reproductive age mirrors any other research peptide — contraception is assumed for the duration of any documented protocol.